Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 8:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 1,781 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Depression; Major Depressive Disorder Clear all
Suspended Phase 1 Interventional

Low Field Magnetic Stimulation (LFMS) in Mood Disorders: 6 Treatments

NCT01557192
View directory record Official record
Conditions
Bipolar Depression, Unipolar Depression
Interventions
Low Field Magnetic Stimulation Device
Device
Lead sponsor
Mclean Hospital
Other
Eligibility
21 Years to 55 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 13, 2016 · Synced Oct 2, 2026, 8:19 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Brain Imaging Techniques That Predict Antidepressant Responsiveness

NCT00909155
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Venlafaxine ERT, Fluoxetine
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2009
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 3, 2018 · Synced Oct 2, 2026, 8:19 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Mood Effects of Serotonin Agonists: Depression

NCT07017478
View directory record Official record
Conditions
LSD, Major Depressive Disorder, Depression
Interventions
LSD, Placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 40 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 2, 2026, 8:19 AM EDT
Completed Phase 3 Interventional Results available

A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD

NCT01372150
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
desvenlafaxine succinate sustained release, fluoxetine, placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
7 Years to 17 Years
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
41
States / cities
Dothan, Alabama • Goodyear, Arizona • Tucson, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2019 · Synced Oct 2, 2026, 8:19 AM EDT
Completed Not applicable Interventional

Treatment for Depressed, Obese Individuals at Risk for Cardiovascular Disease (CVD)

NCT01692574
View directory record Official record
Conditions
Obesity, Major Depressive Disorder, Dysthymic Disorder, Cardiovascular Disease
Interventions
Behavior Modification for Weight Loss, Alternative Approach to Weight Loss, Cognitive-Behavior Therapy for Depression, Depression Support and Education
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 70 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 22, 2016 · Synced Oct 2, 2026, 8:19 AM EDT
Completed Not applicable Interventional

Cognitive Behavioral Therapy for Insomnia with RTMS

NCT04258618
View directory record Official record
Conditions
Depression, Insomnia
Interventions
CBT-I (Cognitive Behavioral Therapy for Insomnia) with rTMS, Repetitive Transcranial Magnetic Stimulation
Behavioral · Device
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 85 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 24, 2024 · Synced Oct 2, 2026, 8:19 AM EDT
Completed Phase 3 Interventional Results available

Brexpiprazole as Adjunctive Therapy With Major Depressive Disorder and an Inadequate Response to Previous Adjunctive Therapy

NCT02012218
View directory record Official record
Conditions
Major Depressive Disorder (MDD)
Interventions
ADT, Brexpiprazole
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
24
States / cities
Garden Grove, California • Temecula, California • Orlando, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2015 · Synced Oct 2, 2026, 8:19 AM EDT
Completed Phase 3 Interventional

Efficacy, Safety and Tolerability of Agomelatine Sublingual Tablets in the Treatment of Major Depressive Disorder

NCT01110889
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Agomelatine (AGO178C), Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
582 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
47
States / cities
Birmingham, Alabama • Beverly Hills, California • Encino, California + 41 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2020 · Synced Oct 2, 2026, 8:19 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Brain Imaging Study in Menopausal Women With and Without Major Depressive Disorder

NCT00626340
View directory record Official record
Conditions
Menopause, Depression
Interventions
MDD diagnosis and Estrogen treatment, MDD diagnosis and Fluoxetine treatment, MDD diagnosis with both Estrogen and Fluoxetine treatment, No depression and estrogen treatment
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
40 Years to 70 Years · Female only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2008
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 1, 2017 · Synced Oct 2, 2026, 8:19 AM EDT
Terminated Phase 4 Interventional Results available

Seroquel Alone Versus Seroquel With an SSRI for Depression With Psychotic Symptoms

NCT00955474
View directory record Official record
Conditions
Major Depressive Disorder With Psychotic Features
Interventions
Quetiapine, escitalopram, Sertraline, Citalopram
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 85 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 20, 2017 · Synced Oct 2, 2026, 8:19 AM EDT
Completed Not applicable Interventional Results available

Testosterone Antidepressant Augmentation in Women

NCT01783574
View directory record Official record
Conditions
Depression
Interventions
Testosterone, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
21 Years to 75 Years · Female only
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
2
States / cities
Boston, Massachusetts • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jun 6, 2018 · Synced Oct 2, 2026, 8:19 AM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers

Partner-Assisted Interpersonal Psychotherapy or Antidepressant Medication for Antenatal Depression

NCT01732055
View directory record Official record
Conditions
Partner Assisted Interpersonal Psychotherapy, Treatment as Usual
Interventions
Partner-Assisted Interpersonal Psychotherapy, Treatment as Usual
Behavioral · Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 45 Years
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 14, 2014 · Synced Oct 2, 2026, 8:19 AM EDT
Completed No phase listed Observational

Brain Network Dynamics of Depression During Esketamine Treatment

NCT06012916
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Esketamine nasal spray
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 99 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 2, 2026, 8:19 AM EDT
Recruiting Phase 2 Interventional

5-HTP and Creatine for Depression R33 Phase

NCT05895747
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Low Dose 5-hydroxytryptophan, High Dose 5-hydroxytryptophan, Low Dose Creatine Monohydrate, High Dose Creatine Monohydrate, Placebo
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 65 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 2, 2026, 8:19 AM EDT
Recruiting Phase 4 Interventional

Aβ Dynamics in LLMD

NCT05004987
View directory record Official record
Conditions
Alzheimer Disease, Major Depressive Disorder
Interventions
Escitalopram Oxalate, Placebo
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
60 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
New York, New York • Orangeburg, New York
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 2, 2026, 8:19 AM EDT
Completed Phase 2 Interventional Results available

Ketamine for the Treatment of Opioid Use Disorder and Depression

NCT04177706
View directory record Official record
Conditions
Depression, Opioid-use Disorder, Opioid Abuse
Interventions
Ketamine Hydrochloride, Placebo
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Aug 7, 2024 · Synced Oct 2, 2026, 8:19 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Treating Smokers With Mental Illness

NCT03822416
View directory record Official record
Conditions
Smoking Cessation, Cigarette Smoking, Schizophrenia, Psychotic Disorders, Major Depressive Disorder, Bipolar Disorder I, Bipolar II Disorder, Mental Illness
Interventions
Nicotine patch, Nicotine lozenge, Therapy, Information
Drug · Behavioral · Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 25, 2021 · Synced Oct 2, 2026, 8:19 AM EDT
Completed Not applicable Interventional

Feasibility of a Behavioral Activation Trial

NCT02992158
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
behavioral activation, treatment-as-usual
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 25, 2020 · Synced Oct 2, 2026, 8:19 AM EDT
Completed Phase 3 Interventional

A Placebo- and Paroxetine-controlled Study of the Efficacy, Safety and Tolerability of Agomelatine (25 or 50 mg) in the Treatment of Major Depressive Disorder (MDD)

NCT00463242
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Agomelatine, paroxetine, placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 70 Years
Enrollment
501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
46
States / cities
Phoenix, Arizona • National City, California • Orange, California + 40 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2020 · Synced Oct 2, 2026, 8:19 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Characterize the Regional Distribution of [11C] ABP688 in Brain by Positron Emission Tomography (PET)

NCT01528241
View directory record Official record
Conditions
Depression
Interventions
ABP688
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
55 Years to 80 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
2
States / cities
New York, New York • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 8, 2020 · Synced Oct 2, 2026, 8:19 AM EDT
Completed Phase 3 Interventional

Risperidone and Suicidality in Major Depressive Disorder

NCT00167154
View directory record Official record
Conditions
Depression
Interventions
Risperidone and placebo comparator
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced Oct 2, 2026, 8:19 AM EDT
Completed Phase 3 Interventional Results available

An Open-label Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder

NCT05061719
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Lumateperone
Drug
Lead sponsor
Intra-Cellular Therapies, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
812 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
40
States / cities
Phoenix, Arizona • Bentonville, Arkansas • Little Rock, Arkansas + 35 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Oct 2, 2026, 8:19 AM EDT
Completed Phase 2 Interventional Results available

Optimization of IV Ketamine for Treatment Resistant Depression

NCT00768430
View directory record Official record
Conditions
Major Depressive Disorder (MDD), Treatment Resistant Depression (TRD)
Interventions
Ketamine, Midazolam
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
21 Years to 80 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
2
States / cities
New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 31, 2014 · Synced Oct 2, 2026, 8:19 AM EDT
Completed No phase listed Observational

Project BEST: Buprenorphine Entry Into Substance Abuse Treatment

NCT02583243
View directory record Official record
Conditions
Opioid-related Disorders, HIV Infections, Hepatitis C, Chronic, Depression
Interventions
MET/CBT based individualized counseling, Buprenorphine
Behavioral · Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 3, 2020 · Synced Oct 2, 2026, 8:19 AM EDT